Raha Samraat S. 4
4 · MYRIAD GENETICS INC · Filed Mar 9, 2026
Research Summary
AI-generated summary of this filing
Myriad Genetics (MYGN) CEO Raha Samraat Buys 40,000 Shares
What Happened
- Raha Samraat S., President & CEO and a director of Myriad Genetics, acquired 40,000 shares on March 9, 2026 in an open-market purchase (transaction code P).
- The filing reports a weighted-average price of $5.00 per share for a total reported value of $199,844.
Key Details
- Transaction date: 2026-03-09.
- Price: weighted-average $5.00; footnote states trades occurred at prices ranging from $4.97 to $5.00 inclusive (reporting person will provide breakdown on request).
- Shares acquired: 40,000 (acquired, not sold).
- Shares owned after transaction: not disclosed in this Form 4 filing.
- Filing timeliness: reported with a Form 4 dated the same day (no late filing indicated).
- No 10b5-1 plan, option exercise, gift, or tax-withholding note included in this filing.
Context
- Insider purchases are often watched by investors as a possible positive signal, but the filing does not state the insider’s motive and does not guarantee future performance.
- This was a straight open-market purchase (P); no derivatives or exercises were involved.
Insider Transaction Report
Form 4
Raha Samraat S.
DirectorPresident and CEO
Transactions
- Purchase
Common Stock
[F1]2026-03-09$5.00/sh+40,000$199,844→ 493,104 total
Footnotes (1)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.97 to $5.00, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Signature
By: Justin Hunter For: Samraat S. Raha|2026-03-09